Anavex sets up trial of ‘triple-action’ Alzheimer’s drug
US biotech Anavex has been cleared to start a phase IIb/III trial of an Alzheimer’s drug that is designed to tackle three features of the disease – amyloid, tau and inflammation.
The company is hoping that by tackling all three characteristics linked to the pathology of Alzheimer’s it may be able to succeed where dozens of other trials – mainly looking at blocking the formation of amyloid deposits in the brain – have failed.
Anavex’ candidate is Anavex 2-73, a sigma-1 receptor (S1R) transmembrane protein activator that is thought to be involved in regulating homeostasis in cells, keeping them in a healthy, steady state by reducing factors such as oxidative stress, protein misfolding, mitochondrial dysfunction and inflammation – all of which are seen in the brains of Alzheimer’s patients.
Read more: http://www.pmlive.com/pharma_news/anavex_sets_up_trial_of_triple-action_alzheimers_drug_1243155
The company is hoping that by tackling all three characteristics linked to the pathology of Alzheimer’s it may be able to succeed where dozens of other trials – mainly looking at blocking the formation of amyloid deposits in the brain – have failed.
Anavex’ candidate is Anavex 2-73, a sigma-1 receptor (S1R) transmembrane protein activator that is thought to be involved in regulating homeostasis in cells, keeping them in a healthy, steady state by reducing factors such as oxidative stress, protein misfolding, mitochondrial dysfunction and inflammation – all of which are seen in the brains of Alzheimer’s patients.
Read more: http://www.pmlive.com/pharma_news/anavex_sets_up_trial_of_triple-action_alzheimers_drug_1243155